Duyuru • Jul 01
Gerresheimer AG Updates Its Earnings Guidance for 2026 Gerresheimer AG updated its earnings guidance for 2026. Due to the challenging economic environment, some project delays on the part of customers, and operational challenges — among others those related to production ramp-ups — the company is adjusting its guidance for financial year 2026. Before M&A and refinancing activities, the Group now expects revenues to be in the lower half of the EUR 2.3 billion to EUR 2.4 billion range (previously EUR 2.3 billion to EUR 2.4 billion). Reported Earnings • Jun 30
Full year 2025 earnings released: €9.27 loss per share (vs €3.18 profit in FY 2024) Full year 2025 results: €9.27 loss per share (down from €3.18 profit in FY 2024). Revenue: €2.32b (up 14% from FY 2024). Net loss: €320.3m (down 392% from profit in FY 2024). Revenue is forecast to grow 4.9% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 32 percentage points per year, which is a significant difference in performance. New Risk • Apr 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swiss stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.0% net profit margin). Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CHF19.52, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 32x in the Life Sciences industry in Switzerland. Total loss to shareholders of 73% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CHF27.96 per share. Duyuru • Apr 11
Gerresheimer AG(XTRA:GXI) dropped from Germany SDAX (Total Return) Index Gerresheimer AG has been dropped from the Germany SDAX (Total Return) Index Valuation Update With 7 Day Price Move • Feb 23
Investor sentiment deteriorates as stock falls 27% After last week's 27% share price decline to CHF18.19, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 28x in the Life Sciences industry in Switzerland. Total loss to shareholders of 71% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CHF28.31 per share. Duyuru • Nov 22
Gerresheimer AG Announces Supervisory Board Changes Klaus Röhrig, co-founder and Co-Chief Investment Officer of the Active Ownership Group, has been appointed to the Supervisory Board of Gerresheimer AG until the next Annual General Meeting in June 2026. He succeeds Dr. Dorothea Wenzel, who made her position available to reflect the changed shareholder structure of the company in the composition of the Supervisory Board. With his appointment, Klaus Röhrig also assumes the duties of Dr. Dorothea Wenzel on the Audit Committee of Gerresheimer AG. Klaus Röhrig will stand for election to the Supervisory Board at the next Annual General Meeting on June 3, 2026. In total, four shareholder representatives will be up for election at the next Annual General Meeting of Gerresheimer AG’s co-determined Supervisory Board. Duyuru • Oct 14
Gerresheimer Ag Announces Fda Grants Approval of Sq Innovation's Lasix®? Onyu Gerresheimer announced that the US Food and Drug Administration (FDA) granted SQ Innovation approval for Lasix ONYU for treatment of edema in congestive heart failure. Lasix ONYU is a combination product consisting of a novel high-concentration formulation of the diuretic furosemide and the Gerresheimer on-body drug delivery device (infusor). It was developed to enable subcutaneous infusion of furosemide at home for selected patients, as prescribed by a clinician without the need for a healthcare professional to administer the drug. The cartridge-based infusor was designed and developed by Gerresheimer based on its proprietary infusor platform for subcutaneous drug delivery. Gerresheimer also manages production of the device as a full-service solution provider. First products of Lasix ONYU are expected to be available on the market already in 2025. The FDA's approval of the combination product demonstrates Gerresheimer's innovative strength and its strong partnership with customers, from product design to large-scale manufacturing. Device based on Gerresheimer's innovative micropump technology: The cartridge-based infus or was designed and developed by Ger Resheimer based on its proprietary infUSor platform for subcutaneous Drug delivery. The core technology is an innovative micropump which enables controlled, precise administration of a drug product according to a defined therapy regimen. Designed with patient comfort and the environment in mind The lightweight, compact device is patched onto the patient's body, making it comfortable for the patient to wear while the drug is gently infused. The reusable component, which is rated for delivery of 48 treatments with diuretic furosemides, is recyclable. Because only the disposable unit requires sterilization, radiation can be used instead of chemical sterilization, and no electronic components end up in medical waste. This two-component concept was developed in line with Gerresheimer's EcoDesign principles, which aim to increase product lifespan and reduce waste. Reducing total cost of care and improving patients' quality of life. The combination product Lasix ONYU also opens up possibilities to reduce the total cost of care. The two-component design results in a lower cost per treatment, because only the disposable part of the device needs to be replaced. Most importantly, the infusor allows for home treatment, reducing the length of hospital stay or avoiding the need for hospitalization for intravenous diuretic administration altogether. First products expected to be available already in 2025 In addition to Gerresheimer's role in design and development, Gerresheimer also manages production the device as a full- service solution provider. The disposable unit for the infusor is, for example, produced at the Gerresheimer facility in Wackersdorf, Germany, on a high-capacity semi-automated line. Production commenced earlier this year in anticipation of approval and first products are expected to be available before the end of the year. Duyuru • Aug 22
Active Ownership Wants Review at Gerresheimer After Taking Stake On August 21, 2025, Active Ownership announced that it saw major potential for value creation at Gerresheimer AG and called for a strategic review. Active Ownership expressly welcomes the planned sale process for the moulded glass division and calls for a swift settlement in order to strengthen the Company's cash flow and reduce debt. Active Ownership also stated that further key measures should include additional portfolio optimization and the implementation of an efficiency programme, particularly through cost reductions in administration and business units. Active Ownership added that this would improve the return on the Company's sales by five percentage points, while also calling for the creation of a strategy committee to review all of the Company's ongoing projects. Duyuru • Jul 11
Gerresheimer AG Provides Revenue Guidance for the Second Half of 2025 Gerresheimer AG provided revenue guidance for the second half of 2025. In the second half of 2025, Gerresheimer expects stronger growth again based on production ramp-ups and a good order intake, and anticipates organic revenue growth of 0 – 2% compared to the previous year. Duyuru • Jun 06
Asset Value Investors Calls for Changes at Gerresheimer AG On June 5, 2025, Asset Value Investors Limited called upon Gerresheimer AG to take steps to restore its market value, a move partially supported by another top 30 investor. Asset Value Investors expressed its views that new financial leadership is needed to restore the Company's relationship and credibility with investors, it said in an open letter to the Company. Asset Value Investors also urged the Company to establish a capital allocation committee and exit its moulded glass business as soon as possible. Union Investment, which holds a 0.9% stake in the Company, said it backed the calls for new leadership and a sale of the moulded glass business but did not see a need for a capital allocation committee. Duyuru • Apr 24
Gerresheimer AG, Annual General Meeting, Jun 05, 2025 Gerresheimer AG, Annual General Meeting, Jun 05, 2025, at 10:00 W. Europe Standard Time. Duyuru • Apr 11
Gerresheimer AG Confirms Earnings Guidance for the Mid-Term of the Fiscal Year 2025 Gerresheimer AG confirmed earnings guidance for the mid-term of the fiscal year 2025. For the mid-term, the company expects organic revenue growth 8% - 10% CAGR. Duyuru • Mar 13
Warburg Pincus, KKR Consortium Reportedly in Talks to Buy Gerresheimer A consortium consisting of Warburg Pincus LLC and KKR & Co. Inc. (NYSE:KKR) are in talks to acquire Gerresheimer AG (ETR:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The private equity firms emerged as the frontrunner after they teamed up and other potential bidders including Bain Capital dropped, the people said, asking not to be identified discussing confidential information. The Warburg Pincus-KKR consortium is unlikely to offer a significant premium to Gerresheimer’s current price and there are still major hurdles to a deal, some of the people said. While the talks are advanced, any final agreement could take weeks and a deal could still fall apart, they added. Representatives for Gerresheimer, Warburg Pincus, KKR and Bain declined to comment. Duyuru • Feb 27
Gerresheimer AG announces Annual dividend, payable on June 10, 2025 Gerresheimer AG announced Annual dividend of EUR 1.2500 per share payable on June 10, 2025, ex-date on June 06, 2025 and record date on June 09, 2025. Duyuru • Feb 21
Phillips-Medisize, Bain Capital Reportedly Eye Gerresheimer US medical solutions company Phillips-Medisize (Phillips-Medisize, LLC) and buyout firm Bain Capital (Bain Capital, LP) are among potential bidders for Gerresheimer AG (XTRA:GXI), the German maker of packaging for drugs and cosmetics, according to people familiar with the matter. The firms join other suitors that have been evaluating possible offers for part or all of Gerresheimer, the people said, asking not to be identified because the information is private. Duyuru • Feb 20
Gerresheimer AG to Report Q3, 2025 Results on Oct 10, 2025 Gerresheimer AG announced that they will report Q3, 2025 results on Oct 10, 2025 Duyuru • Feb 11
Gerresheimer Discussing Takeover with Private Equity Investors German pill bottles and syringes maker Gerresheimer AG (XTRA:GXI) said on February 07, 2025 that it is in early-stage talks with private equity investors over a potential takeover, confirming a media report. The private equity firms have expressed, on an informal and non-binding basis, their interest to explore a possible public takeover offer for Gerresheimer, the company said. The discussions are still in a very preliminary stage and it is not certain at this point whether an offer will actually be made, the firm added, without disclosing further details. The statement was made after news agency Bloomberg previously reported that private equity firms Warburg Pincus LLC, EQT AB (publ) (OM:EQT) and KKR & Co. Inc. (NYSE:KKR) among other suitors have shown interest in the German pill bottles and syringes maker. Reported Earnings • Oct 01
Third quarter 2024 earnings released: EPS: €1.16 (vs €0.81 in 3Q 2023) Third quarter 2024 results: EPS: €1.16 (up from €0.81 in 3Q 2023). Revenue: €498.5m (up 2.2% from 3Q 2023). Net income: €40.1m (up 43% from 3Q 2023). Profit margin: 8.0% (up from 5.7% in 3Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Jul 12
Second quarter 2024 earnings released: EPS: €0.94 (vs €1.05 in 2Q 2023) Second quarter 2024 results: EPS: €0.94 (down from €1.05 in 2Q 2023). Revenue: €502.4m (flat on 2Q 2023). Net income: €32.5m (down 5.7% from 2Q 2023). Profit margin: 6.5% (down from 6.9% in 2Q 2023). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Upcoming Dividend • May 30
Upcoming dividend of €1.25 per share Eligible shareholders must have bought the stock before 06 June 2024. Payment date: 10 June 2024. Payout ratio is a comfortable 36% but the company is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of Swiss dividend payers (4.1%). Higher than average of industry peers (0.8%). New Risk • May 29
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swiss stocks, typically moving 7.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (7.4% average weekly change). Minor Risk High level of debt (69% net debt to equity). New Risk • Apr 17
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 69% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (69% net debt to equity). Share price has been volatile over the past 3 months (6.1% average weekly change). Shareholders have been diluted in the past year (10.0% increase in shares outstanding). Reported Earnings • Apr 11
First quarter 2024 earnings released: EPS: €0.38 (vs €0.38 in 1Q 2023) First quarter 2024 results: EPS: €0.38. Revenue: €466.1m (up 1.8% from 1Q 2023). Net income: €13.0m (up 8.0% from 1Q 2023). Profit margin: 2.8% (up from 2.6% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10.0% p.a. on average during the next 3 years, compared to a 9.9% growth forecast for the Life Sciences industry in Switzerland. Duyuru • Apr 11
Gerresheimer AG Provides Earnings Guidance for the Year 2024 and 2025 Gerresheimer AG provided earnings guidance for the year 2024 and 2025. For the year 2024, the company expects revenue growth of 5% to 10%.For the year 2025, the company expects revenue growth of 10% to 15%. Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CHF75.60, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 38x in the Life Sciences industry in Switzerland. Total returns to shareholders of 5.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CHF119 per share. Declared Dividend • Feb 25
Dividend of €1.25 announced Shareholders will receive a dividend of €1.25. Ex-date: 6th June 2024 Payment date: 10th June 2024 Dividend yield will be 1.7%, which is higher than the industry average of 0.9%. Reported Earnings • Feb 23
Full year 2023 earnings released: EPS: €3.48 (vs €3.06 in FY 2022) Full year 2023 results: EPS: €3.48 (up from €3.06 in FY 2022). Revenue: €1.99b (up 9.5% from FY 2022). Net income: €116.1m (up 21% from FY 2022). Profit margin: 5.8% (up from 5.3% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Buying Opportunity • Jan 08
Now 30% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be CHF93.39, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 9.0% per annum. Earnings is also forecast to grow by 22% per annum over the same time period. Buying Opportunity • Dec 20
Now 31% undervalued after recent price drop Over the last 90 days, the stock is down 14%. The fair value is estimated to be CHF94.21, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 9.0% per annum. Earnings is also forecast to grow by 22% per annum over the same time period. New Risk • Oct 06
New minor risk - Financial position The company has a high level of debt. Net debt to equity ratio: 62% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (62% net debt to equity). Shareholders have been diluted in the past year (10.0% increase in shares outstanding). Reported Earnings • Oct 06
Third quarter 2023 earnings released: EPS: €0.81 (vs €0.87 in 3Q 2022) Third quarter 2023 results: EPS: €0.81. Revenue: €487.9m (up 3.2% from 3Q 2022). Net income: €28.0m (up 2.5% from 3Q 2022). Profit margin: 5.7% (down from 5.8% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Duyuru • Oct 06
Gerresheimer AG Provides Earnings Guidance for Full Year 2023 Gerresheimer AG provided earnings guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%. Reported Earnings • Jul 07
Second quarter 2023 earnings released: EPS: €1.05 (vs €0.80 in 2Q 2022) Second quarter 2023 results: EPS: €1.05 (up from €0.80 in 2Q 2022). Revenue: €499.6m (up 12% from 2Q 2022). Net income: €34.4m (up 37% from 2Q 2022). Profit margin: 6.9% (up from 5.7% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Duyuru • Jul 06
Gerresheimer Ag Provides Revenue Guidance for Full Year 2023 Gerresheimer AG provided revenue guidance for full year 2023. For the year, the company expects Organic revenue growth: at least 10% and Medium-term guidance (for group level, currency-adjusted), Organic revenue growth: at least 10%. Duyuru • Jun 08
Gerresheimer AG Announces Dividend for the Financial Year 2022, Payable on June 12, 2023 Gerresheimer AG announced a dividend of EUR 1.25 for the financial year 2022. The dividend is to be paid out on June 12, 2023. Upcoming Dividend • Jun 01
Upcoming dividend of €1.25 per share at 1.2% yield Eligible shareholders must have bought the stock before 08 June 2023. Payment date: 12 June 2023. Payout ratio is a comfortable 40% but the company is not cash flow positive. Trailing yield: 1.2%. Lower than top quartile of Swiss dividend payers (4.4%). Higher than average of industry peers (0.6%). Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CHF75.60, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 39x in the Life Sciences industry in Switzerland. Total returns to shareholders of 5.7% over the past three years. Reported Earnings • Apr 08
First quarter 2023 earnings released: EPS: €0.38 (vs €0.34 in 1Q 2022) First quarter 2023 results: EPS: €0.38 (up from €0.34 in 1Q 2022). Revenue: €457.8m (up 24% from 1Q 2022). Net income: €12.0m (up 12% from 1Q 2022). Profit margin: 2.6% (down from 2.9% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CHF75.60, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 37x in the Life Sciences industry in Switzerland. Total returns to shareholders of 5.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CHF43.11 per share. Reported Earnings • Feb 24
Full year 2022 earnings released: EPS: €3.06 (vs €2.67 in FY 2021) Full year 2022 results: EPS: €3.06 (up from €2.67 in FY 2021). Revenue: €1.82b (up 21% from FY 2021). Net income: €96.1m (up 15% from FY 2021). Profit margin: 5.3% (down from 5.6% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CHF75.60, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 36x in the Life Sciences industry in Switzerland. Total returns to shareholders of 5.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CHF54.45 per share. Valuation Update With 7 Day Price Move • Jan 29
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CHF75.60, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 35x in the Life Sciences industry in Switzerland. Total returns to shareholders of 5.7% over the past three years. Reported Earnings • Oct 16
Third quarter 2022 earnings released: EPS: €0.87 (vs €0.61 in 3Q 2021) Third quarter 2022 results: EPS: €0.87 (up from €0.61 in 3Q 2021). Revenue: €473.0m (up 24% from 3Q 2021). Net income: €27.3m (up 43% from 3Q 2021). Profit margin: 5.8% (up from 5.0% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Switzerland. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Jul 14
Second quarter 2022 earnings released: EPS: €0.80 (vs €0.90 in 2Q 2021) Second quarter 2022 results: EPS: €0.80 (down from €0.90 in 2Q 2021). Revenue: €444.6m (up 18% from 2Q 2021). Net income: €25.2m (down 11% from 2Q 2021). Profit margin: 5.7% (down from 7.5% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 7.5%, compared to a 14% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Jun 02
Upcoming dividend of €1.25 per share Eligible shareholders must have bought the stock before 09 June 2022. Payment date: 13 June 2022. Payout ratio is a comfortable 46% but the company is paying out more than the cash it is generating. Trailing yield: 1.8%. Lower than top quartile of Swiss dividend payers (3.9%). Higher than average of industry peers (0.6%). Reported Earnings • Apr 08
First quarter 2022 earnings released: EPS: €0.34 (vs €0.29 in 1Q 2021) First quarter 2022 results: EPS: €0.34 (up from €0.29 in 1Q 2021). Revenue: €370.8m (up 22% from 1Q 2021). Net income: €10.7m (up 17% from 1Q 2021). Profit margin: 2.9% (in line with 1Q 2021). Over the next year, revenue is forecast to grow 6.5%, compared to a 33% growth forecast for the industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Reported Earnings • Feb 19
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: €2.67 (down from €2.82 in FY 2020). Revenue: €1.50b (up 5.6% from FY 2020). Net income: €83.8m (down 5.4% from FY 2020). Profit margin: 5.6% (down from 6.2% in FY 2020). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 8.4%, compared to a 37% growth forecast for the pharmaceuticals industry in Switzerland. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Reported Earnings • Oct 13
Third quarter 2021 earnings released: EPS €0.61 (vs €0.81 in 3Q 2020) The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: €382.0m (up 9.4% from 3Q 2020). Net income: €19.1m (down 25% from 3Q 2020). Profit margin: 5.0% (down from 7.3% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings. Reported Earnings • Jul 14
Second quarter 2021 earnings released: EPS €0.90 (vs €0.92 in 2Q 2020) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2021 results: Revenue: €377.0m (up 3.9% from 2Q 2020). Net income: €28.1m (down 3.0% from 2Q 2020). Profit margin: 7.5% (down from 8.0% in 2Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 2% per year, which means it has not declined as severely as earnings. Upcoming Dividend • Jun 03
Upcoming dividend of €1.25 per share Eligible shareholders must have bought the stock before 10 June 2021. Payment date: 14 June 2021. Trailing yield: 1.4%. Lower than top quartile of Swiss dividend payers (3.4%). Higher than average of industry peers (0.5%). Reported Earnings • Apr 10
First quarter 2021 earnings released: EPS €0.29 (vs €0.13 in 1Q 2020) The company reported a decent first quarter result with improved earnings and profit margins, although revenues were flat. First quarter 2021 results: Revenue: €302.8m (flat on 1Q 2020). Net income: €9.20m (up 122% from 1Q 2020). Profit margin: 3.0% (up from 1.4% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Is New 90 Day High Low • Feb 15
New 90-day low: CHF65.15 The company is down 14% from its price of CHF75.60 on 17 November 2020. The Swiss market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF63.57 per share. Is New 90 Day High Low • Jan 28
New 90-day low: CHF65.15 The company is down 14% from its price of CHF75.60 on 30 October 2020. The Swiss market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF83.90 per share. Is New 90 Day High Low • Jan 13
New 90-day low: CHF65.15 The company is down 14% from its price of CHF75.60 on 15 October 2020. The Swiss market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF68.98 per share. Is New 90 Day High Low • Dec 29
New 90-day low: CHF65.15 The company is down 14% from its price of CHF75.60 on 30 September 2020. The Swiss market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CHF70.50 per share. Reported Earnings • Oct 14
Third quarter earnings released Over the last 12 months the company has reported total losses of €24.7m, with earnings decreasing by €230.4m from the prior year. Total revenue was €1.38b over the last 12 months, down 2.1% from the prior year. Analyst Estimate Surprise Post Earnings • Oct 14
Third-quarter earnings released: Revenue misses expectations Third-quarter revenue missed analyst estimates by 1.3% at €349.2m. Revenue is forecast to grow 7.6% over the next year, compared to a 16% growth forecast for the Life Sciences industry in Switzerland. 
